News About: Pharm. Affairs
Green Cross’s Hunterase approved to conduct Phase 2 clinical trials in USGreen Cross’s rare disease therapies will challenge the U.S. market.
On the 12th, Green Cross(CEO Eun-cheol Huh) announced recent acquisition of approval to start Phase 2 clini...
|
Amgen collected domestic licenses of 3 biomedicines from GSKAmgen, which officially established a Korean branch, collected domestic licenses of 3 biomedicines that were handed to GSK. They are blockbuster drugs which globally recorded US...
|
4th NOAC ‘Lixiana’ landed in 4 of ‘Big 5’ hospitals
A series of news about the 4th NOAC ‘Lixiana(edoxaban)’ to land in general hospitals have continuously followed.
According to the industry concerned on the 13th, Lixiana, the new oral anti-coagulant(NOAC) jointly so...
Finally, Gardasil and Cervarix join in NIP with different prices
On the 12th, the Korea Centers for Disease Control and Prevention(KCDC) announced to make separated agreements on each cervical cancer vaccine which will be vaccinated for children for the age 12 from this June. Like ...
Daewoong-AZ Korea start to jointly sell hyperlipidemia treatment ‘Crestor’
On the 11th, Daewoong Pharmaceutical(CEO Jong-ok Lee) announced it made a strategic joint sales agreement of ‘Crestor(generic name: rosuvastatin),’ a hyperlipidemia treatment, with AstraZeneca(CEO Liz Chatwin), and st...
GSK and Bayer pushed out from ranking competition, recording low performances
In Korea, sales of GSK(GlaxoSmithKline) and Bayer have continuously decreased.
According to 2015 audit reports turned in to the Financial Supervisory Service, GSK and Bayer Korea were reduced in sales last year compa...
Zykadia Cap passes first wall of insurance benefit registration
A Novartis’s lung cancer therapy, Zykadia Cap(ceritinib) received a ‘insurance benefit adequacy’ evaluation as applied by a special case to be exempted in economic evaluation. It, thus, became the 5th drug which passe...
Hair loss therapies 70% cheaper than Propecia
Hair loss therapies will be sold with cheaper prices due to generic launches. A drug that is 70% cheaper at most than Propecia(MSD), a drug sold the most in Korea, launched.
According to the industry on the 7th, a n...
Celltrion’s ‘Remsima’ approve from U.S. FDA, challenging KRW 20 trillion market
Celltrion announced acquisition of U.S. sales approval of the first biosimilar antibody Remsima from the U.S. Food and Drug Administration(hereinafter referring to FDA) on April 5(local time).
The FDA particularly ap...
Korea-Mexico USD 23.5 billion healthcare industry opened
The government put efforts to support entry of the pharmaceutical industry into Mexico for the ‘2nd Kanarb’ legend.
Taking the President Geun-hye Park’s visit to Mexico as an opportunity, the Ministry of Health and ...
